SWTX SpringWorks Therapeutics

SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks' strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with industry leaders to expand its portfolio.

SWTX stock data


Press releases

From Benzinga Pro
SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refractory Multiple Myeloma
27 Oct 21
-- Based on Encouraging Preliminary Data Observed with the First Dose Exploration Cohort (0.95 mg/kg BLENREP Q3W + Nirogacestat) a Randomized Phase 2 Cohort Expansion to Compare Against 2.5 mg/kg Q3W BLENREP Monotherapy
SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Generation Targeted Oncology Therapeutics
20 Oct 21
– SpringWorks to Utilize Pioneering Computational Modeling Approaches Developed by Yibing Shan, Ph.D., Previously Founding Member of DE Shaw Research and Leading Computational Structural Biologist – – Collaboration
SpringWorks Therapeutics to Collaborate with Leading Academic Institutions to Advance Portfolio of Next-Generation Mutation-Selective EGFR Inhibitors
20 Oct 21
- Portfolio is Currently in Lead Optimization and Includes Several Novel Approaches for Targeting Mutant EGFR that are Designed to Address Both De Novo Oncogenic Drivers and Emerging Resistance Mutations - - Chemistry
SpringWorks Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
7 Sep 21
SpringWorks Therapeutics Enters into Research Collaboration with Leading Cancer Institute to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma
30 Aug 21

Investment data

Data from SEC filings
Securities sold
Number of investors


4 Aug 21
28 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 85.14M 85.14M 85.14M 85.14M 85.14M 85.14M
Cash burn (monthly) 3.62M 11.84M 15.67M 7.26M 11.18M 4.52M
Cash used (since last report) 14.34M 46.94M 62.13M 28.79M 44.3M 17.93M
Cash remaining 70.79M 38.2M 23.01M 56.35M 40.84M 67.21M
Runway (months of cash) 19.6 3.2 1.5 7.8 3.7 14.9

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
20 Oct 21 Saqib Islam Common Stock Sell Dispose S No Yes 58.6658 10,083 591.53K 779,218
19 Oct 21 Saqib Islam Common Stock Sell Dispose S No Yes 58.8103 14,077 827.87K 769,135
18 Oct 21 Saqib Islam Common Stock Sell Dispose S No Yes 58.5943 38,340 2.25M 783,212
13 Oct 21 L. Mary Smith Common Stock Sell Dispose S No Yes 55.9675 10,000 559.68K 167,511
13 Oct 21 L. Mary Smith Common Stock Option exercise Acquire M No Yes 2.3 10,000 23K 177,511
13 Oct 21 L. Mary Smith Stock Option Common Stock Option exercise Dispose M No Yes 2.3 10,000 23K 84,296
8 Sep 21 Daniel Pichl Common Stock Option exercise Acquire M No No 43.1 2,320 99.99K 9,236
8 Sep 21 Daniel Pichl Stock Option Common Stock Option exercise Dispose M No No 43.1 2,320 99.99K 72,680
10 Aug 21 Bain Capital Life Sciences Investors Common Stock Sell Dispose S Yes No 70.25 1,000,000 70.25M 4,831,307

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 136 139 -2.2%
Opened positions 20 26 -23.1%
Closed positions 23 14 +64.3%
Increased positions 59 51 +15.7%
Reduced positions 36 46 -21.7%
13F shares
Current Prev Q Change
Total value 4.41B 4.1B +7.7%
Total shares 54.62M 53.88M +1.4%
Total puts 2.7K 0 NEW
Total calls 0 0
Total put/call ratio Infinity
Largest owners
Shares Value Change
Orbimed Advisors 6.04M $498.11M -2.3%
Bain Capital Life Sciences Investors 5.83M $480.56M 0.0%
BC SW 5.83M $437.87M 0.0%
Perceptive Advisors 4.85M $399.68M 0.0%
PFE Pfizer 4.58M $332.36M 0.0%
FMR 3.97M $327.02M +4.7%
Vanguard 2.71M $223.01M +8.5%
BLK Blackrock 2.49M $204.9M +9.6%
Boxer Capital 2.08M $171.08M 0.0%
Driehaus Capital Management 1.38M $113.38M +9.0%
Largest transactions
Shares Bought/sold Change
BAC Bank Of America 772.46K +271.91K +54.3%
Caas Capital Management 0 -224.89K EXIT
BLK Blackrock 2.49M +216.79K +9.6%
Vanguard 2.71M +212.01K +8.5%
FMR 3.97M +176.85K +4.7%
Orbimed Advisors 6.04M -142.04K -2.3%
Jennison Associates 313.66K +128.57K +69.5%
BMO Bank of Montreal 117.27K +116.32K +12270.4%
Driehaus Capital Management 1.38M +113.7K +9.0%
Cormorant Asset Management 15K -110K -88.0%

Financial report summary

  • Summary of company specific material risk factors
  • Our business is highly dependent on the success of our lead product candidates, nirogacestat and mirdametinib, as well as other product candidates we may develop. If we are unable to successfully complete clinical development of, obtain regulatory approval for or commercialize our product candidates, or if we experience delays in doing so, our business will be materially harmed.
  • Interim “topline” and preliminary data from our clinical trials that we announce or publish from time to time may change as more data become available, are not necessarily predictive of the final results of the completed study or the results of other ongoing or future studies and are subject to audit and verification procedures that could result in material changes to the final data.*
  • As an organization, we have never successfully completed any registrational clinical trials, and we may be unable to do so for any product candidates we may develop.
  • If we encounter difficulties enrolling patients in any of our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
  • Risks related to our reliance on third parties
  • We rely on third parties to conduct certain aspects of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for, or commercialize, any potential product candidates.*
  • Because we rely on third-party manufacturing and supply partners, our supply of preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality.
  • Our existing and future collaborations will be important to our business. If we are unable to maintain our existing collaborations or enter into new collaborations, or if these collaborations are not successful, our business could be adversely affected. In addition, our collaborators have broad discretion in many aspects of their performance of collaboration activities and they may take actions with which we do not agree.*
  • We depend on intellectual property licensed from third parties, including from Pfizer for our lead product candidates, and termination of any of these licenses could result in the loss of significant rights, which would harm our business.
  • If we fail to comply with our obligations under our patent licenses with third parties, we could lose license rights that are important to our business.
  • We have been granted Orphan Drug Designation for nirogacestat and mirdametinib and may seek Orphan Drug Designation for other product candidates, but we may be unable to obtain or maintain such designation or the benefits associated with such designation, including the potential for market exclusivity, which may negatively impact our financial performance.*
  • Our current operations are concentrated in two locations, and we or the third parties upon whom we depend may be adversely affected by natural disasters or other unforeseeable or uncontrollable events and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.*
  • Risks related to our financial position and need for additional capital
  • We have incurred significant net losses since our inception and anticipate that we will continue to incur net losses in the future.
  • We have a limited operating history, which may make it difficult to evaluate our prospects and likelihood of success.*
  • We will require additional capital to fund our operations and if we fail to obtain necessary capital, we will not be able to complete the development and commercialization of our product candidates.
  • Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
  • Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.
  • Our bylaws designate certain specified courts as the sole and exclusive forums for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
  • Clinical development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
  • Our success depends in part on our ability to protect our intellectual property, and patent terms may be inadequate to protect our competitive position. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.*
  • Third parties may assert that our employees, consultants, collaborators or partners have wrongfully used or disclosed confidential information or misappropriated trade secrets.
  • We may not be able to protect our intellectual property rights throughout the world.
  • The regulatory approval process for our product candidates in the U.S., the European Union, and other jurisdictions is currently uncertain and will be lengthy, time-consuming and inherently unpredictable and we may experience significant delays in the clinical development and regulatory approval, if any, of our product candidates.*
  • The FDA, EMA or comparable foreign regulatory authorities may disagree with our regulatory plan for our product candidates.
  • Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably.*
  • Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.*
  • Disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.*
  • We may incur substantial costs in our efforts to comply with evolving global data protection laws and regulations, and any failure or perceived failure by us to comply with such laws and regulations may harm our business and operations.
  • Additional laws and regulations governing international operations could negatively impact or restrict our operations.
  • We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations.
  • The outbreak of the novel coronavirus disease, COVID-19, could adversely impact our business, including our preclinical studies and clinical trials.*
  • Our internal computer systems, or those used by our vendors, or other contractors or consultants, may fail or suffer security breaches.
  • The price of our stock may be volatile, and Stockholders could lose all or part of their investment.
  • We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to new and existing compliance initiatives.
  • If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.
Content analysis
H.S. senior Avg
New words: adolescent, begun, breast, combat, concurrent, Conference, constitutionality, Daniel, degrader, disability, dismissed, Domain, equal, estrogen, feature, felt, fulvestrant, glioma, Herschel, Hippo, inseverable, instructed, Jude, Katholieke, Kettering, KU, lessening, Leuven, Memorial, Michael, monoclonal, MSK, NF, oncogenic, Pichl, platform, preapproval, reconsider, referenced, remanded, rollout, Seagen, signaling, Sloan, St, TEA, TEAD, tiered, transcription, unconstitutional, uncontrollable, unforeseeable, Universiteit, unnecessary, variant, VIB, waiver, Weinstein, widespread, workforce, young
Removed: aimed, burden, capability, constitutional, emergence, founding, invested, Renstrup, repealing, revising